Adlai Nortye (NASDAQ:ANL) Shares Gap Down to $14.80

Adlai Nortye Ltd. (NASDAQ:ANL) gapped down before the market opened on Tuesday . The stock had previously closed at $14.80, but opened at $13.83. Adlai Nortye shares last traded at $13.83, with a volume of 444 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Adlai Nortye in a research note on Friday, January 12th.

Adlai Nortye Stock Down 8.5 %

The stock has a 50-day simple moving average of $9.60 and a 200 day simple moving average of $9.34.

Hedge Funds Weigh In On Adlai Nortye

A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. grew its position in Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 40,310 shares of the company’s stock after buying an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned 0.11% of Adlai Nortye worth $362,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 35.21% of the company’s stock.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.